GENFIT (GNFT.PA) Stock Fundamental Analysis
EPA:GNFT - Euronext Paris - Matif - FR0004163111 - Common Stock - Currency: EUR
GNFT gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 73 industry peers in the Biotechnology industry. There are concerns on the financial health of GNFT while its profitability can be described as average. GNFT is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
GNFT had positive earnings in the past year.
In the past year GNFT had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: GNFT reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: GNFT reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of 1.00%, GNFT is in the better half of the industry, outperforming 72.60% of the companies in the same industry.
GNFT has a Return On Equity of 2.18%. This is in the better half of the industry: GNFT outperforms 75.34% of its industry peers.
GNFT has a better Return On Invested Capital (3.45%) than 82.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1% | ||
| ROE | 2.18% | ||
| ROIC | 3.45% |
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of GNFT (2.12%) is better than 75.34% of its industry peers.
In the last couple of years the Profit Margin of GNFT has declined.
With an excellent Operating Margin value of 4.55%, GNFT belongs to the best of the industry, outperforming 80.82% of the companies in the same industry.
GNFT's Operating Margin has declined in the last couple of years.
GNFT has a Gross Margin of 97.11%. This is amongst the best in the industry. GNFT outperforms 95.89% of its industry peers.
In the last couple of years the Gross Margin of GNFT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.55% | ||
| PM (TTM) | 2.12% | ||
| GM | 97.11% |
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so GNFT is destroying value.
GNFT has more shares outstanding than it did 1 year ago.
GNFT has more shares outstanding than it did 5 years ago.
GNFT has a worse debt/assets ratio than last year.
2.2 Solvency
GNFT has an Altman-Z score of -1.47. This is a bad value and indicates that GNFT is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of GNFT (-1.47) is worse than 60.27% of its industry peers.
The Debt to FCF ratio of GNFT is 4.26, which is a neutral value as it means it would take GNFT, 4.26 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.26, GNFT belongs to the top of the industry, outperforming 84.93% of the companies in the same industry.
A Debt/Equity ratio of 0.08 indicates that GNFT is not too dependend on debt financing.
GNFT has a better Debt to Equity ratio (0.08) than 68.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | 4.26 | ||
| Altman-Z | -1.47 |
ROIC/WACC0.45
WACC7.7%
2.3 Liquidity
A Current Ratio of 1.23 indicates that GNFT should not have too much problems paying its short term obligations.
With a Current ratio value of 1.23, GNFT is not doing good in the industry: 68.49% of the companies in the same industry are doing better.
A Quick Ratio of 1.23 indicates that GNFT should not have too much problems paying its short term obligations.
GNFT has a Quick ratio of 1.23. This is in the lower half of the industry: GNFT underperforms 64.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.23 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 105.17% over the past year.
Measured over the past years, GNFT shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -70.77% on average per year.
The Revenue has grown by 85.82% in the past year. This is a very strong growth!
GNFT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.61% yearly.
EPS 1Y (TTM)105.17%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-212.5%
Revenue 1Y (TTM)85.82%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-53%
3.2 Future
Based on estimates for the next years, GNFT will show a very negative growth in Earnings Per Share. The EPS will decrease by -45.31% on average per year.
GNFT is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.83% yearly.
EPS Next Y-118.61%
EPS Next 2Y-45.31%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3.14%
Revenue Next 2Y-20.11%
Revenue Next 3Y10.24%
Revenue Next 5Y-1.83%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 134.07, GNFT can be considered very expensive at the moment.
Based on the Price/Earnings ratio, GNFT is valued a bit cheaper than the industry average as 78.08% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of GNFT to the average of the S&P500 Index (26.25), we can say GNFT is valued expensively.
The Forward Price/Earnings Ratio is negative for GNFT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 134.07 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, GNFT is valued a bit cheaper than 73.97% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, GNFT is valued cheaply inside the industry as 91.78% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.76 | ||
| EV/EBITDA | 36.55 |
4.3 Compensation for Growth
A cheap valuation may be justified as GNFT's earnings are expected to decrease with -45.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-45.31%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for GNFT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:GNFT (5/30/2025, 7:00:00 PM)
4.022
+0.11 (+2.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.9%
Inst Owner ChangeN/A
Ins Owners0.19%
Ins Owner ChangeN/A
Market Cap200.54M
Analysts90.77
Price Target9.66 (140.18%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.07%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)84.96%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)4.87%
Revenue NY rev (3m)117.93%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 134.07 | ||
| Fwd PE | N/A | ||
| P/S | 2.83 | ||
| P/FCF | 13.76 | ||
| P/OCF | 12.9 | ||
| P/B | 2.9 | ||
| P/tB | 9.45 | ||
| EV/EBITDA | 36.55 |
EPS(TTM)0.03
EY0.75%
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)0.29
FCFY7.27%
OCF(TTM)0.31
OCFY7.75%
SpS1.42
BVpS1.39
TBVpS0.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1% | ||
| ROE | 2.18% | ||
| ROCE | 4.23% | ||
| ROIC | 3.45% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 4.55% | ||
| PM (TTM) | 2.12% | ||
| GM | 97.11% | ||
| FCFM | 20.54% |
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
F-Score7
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | 4.26 | ||
| Debt/EBITDA | 1.12 | ||
| Cap/Depr | 56.79% | ||
| Cap/Sales | 1.38% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 314.19% | ||
| Profit Quality | 966.82% | ||
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.23 | ||
| Altman-Z | -1.47 |
F-Score7
WACC7.7%
ROIC/WACC0.45
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)105.17%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-212.5%
EPS Next Y-118.61%
EPS Next 2Y-45.31%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)85.82%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-53%
Revenue Next Year3.14%
Revenue Next 2Y-20.11%
Revenue Next 3Y10.24%
Revenue Next 5Y-1.83%
EBIT growth 1Y112.1%
EBIT growth 3Y-53.58%
EBIT growth 5YN/A
EBIT Next Year67.69%
EBIT Next 3Y62.39%
EBIT Next 5YN/A
FCF growth 1Y125.16%
FCF growth 3Y-47.27%
FCF growth 5YN/A
OCF growth 1Y128.05%
OCF growth 3Y-46.21%
OCF growth 5YN/A